Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2016 -- Strongbridge Biopharma plc (NASDAQ:SBBP) today announced that Matthew Pauls, president and chief executive officer, is scheduled to present a corporate overview at two upcoming investor conferences in March.
Cowen and Company 36th Annual Health Care Conference
Date: Tuesday, March 8, 2016
Time: 10:00 a.m. EST
Location: Boston, MA
28th Annual ROTH Conference
Date: Monday, March 14, 2016
Time: 9:30 a.m. PST
Location: Dana Point, CA
Both presentations will be webcast live and available on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. Strongbridge Biopharma's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. Strongbridge Biopharma recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for the treatment of acromegaly and designed to block the synthesis of growth hormone receptor (GHr), thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. COR-003 and COR-005 have received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration, and the Company is pursuing orphan designation for COR-004. Strongbridge Biopharma's intent is to independently commercialize its rare endocrine assets in key global markets.
Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations ICR Inc. Stephanie Carrington +1 646-277-1282 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
